口服生物可用的环素A/B RxL抑制剂:优化一种新型宏环类的优化,针对E2F高和G1-S检查点受损的癌症
Justin A Shapiro1, Nathan J Dupper1, Breena Fraga-Walton1
1Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States.
Journal of medicinal chemistry
|February 21, 2026
概括
研究人员开发了口服可用的宏环,针对Cyclin A/B治疗小细胞肺癌 (SCLC). 这些化合物有选择性地杀死癌细胞,并在临床前模型中显示瘤回归,目前在第一阶段临床试验中有一种主要候选物.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 循环素A和B通过激活循环素依赖激酶 (CDKs) 来调节细胞循环的进展.
- 涉及RxL动机的环林-疏水补丁 (HP) 相互作用对于招募基质和调节剂至关重要.
- 向Cyclin A/B为具有高E2F活性的癌症提供了潜在的治疗策略.
研究的目的:
- 优化抑制Cyclin A/B的宏环,以改善类似药物的特性和口服生物可用性.
- 在小细胞肺癌 (SCLC) 模型中发现用于口服的化合物.
- 在临床评估中推进环林A/B抑制剂.
主要方法:
- 针对Cyclin A/B疏水补丁 (HP) 的宏环的设计和合成.
- 优化化合物的口服生物可用性和类似药物的特性.
- 在口服剂后SCLC的细胞衍生异种移植 (CDX) 模型中评估瘤回归.
主要成果:
- 识别与环素A和B结合的被动透性宏环.HP.
- 在具有高E2F活性的细胞中,选择性杀死癌细胞的证明.
- 在SCLC CDX模型中通过口服给药发现了一种优化的化合物,该化合物显示瘤回归.
- 克林A/B抑制的成功推进进入一期临床试验.
结论:
- 针对Cyclin A/B的优化宏环呈现出有希望的抗癌活性和口服生物可用性.
- 化合物在临床前SCLC模型中显示出有效性,支持其临床潜力.
- 环素A/B抑制是目前正在临床研究中的SCLC的一种可行的治疗方法.
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Positive Regulator Molecules
7.0K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Positive Regulator Molecules
136.7K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
136.7K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


